Vanguard Capital Management
ESPR

Vanguard Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Vanguard Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.1M Buy
11,427,437
+993,677
+10% +$2.78M ﹤0.01% 2124
2026
Q1 		$28.6M Buy
+10,433,760
New +$33M ﹤0.01% 2157

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management's ESPR Position: Q2 2026 in Review

Vanguard Capital Management increased its Esperion Therapeutics (ESPR) stake by 9.5% in Q2 2026, buying an estimated $2.78M and bringing the position to 11,427,437 shares worth $36.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2124.

Vanguard Capital Management first reported a position in ESPR in Q1 2026 and has held it in 2 quarters since. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Vanguard Capital Management held 11,427,437 shares of Esperion Therapeutics worth $36.1M as of Q2 2026.
  • Vanguard Capital Management bought 993,677 Esperion Therapeutics shares in Q2 2026, an estimated $2.78M.
  • Esperion Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2124 holding.
  • Vanguard Capital Management first reported a position in Esperion Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.